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BACKGROUND: Deep brain stimulation (DBS) of the anterior nucleus of the thalamus
(ANT) is an effective therapy for patients with drug-resistant focal epilepsy. Best practices
for surgical targeting of the ANT can be refined as new information becomes available
regarding effective stimulation sites.
OBJECTIVE: To conduct a retrospective analysis of the relationship between outcomes
(seizure reduction during year 1) and DBS lead locations in subjects from the SANTÉ pivotal
trial (Stimulation of ANT for Epilepsy) based upon recent clinical findings.
METHODS: Postoperative images from SANTÉ subjects (n = 101) were evaluated with
respect to lead trajectory relative to defined anatomic landmarks. A qualitative scoring
system was used to rate each lead placement for proximity to an identified target
region above the junction of the mammillothalamic tract with the ANT. Each subject was
assigned a bilateral lead placement score, and these scores were then compared to clinical
outcomes.
RESULTS: Approximately 70% of subjects had “good” bilateral lead placements based
upon location with respect to the defined target. These subjects had a much higher
probability of being a clinical responder (>50% seizure reduction) than those with scores
reflecting suboptimal lead placements (43.5% vs 21.9%, P < .05).
CONCLUSION: Consistent with experience from more established DBS indications, our
findings and other recent reports suggest that there may be specific sites within
the ANT that are associated with superior clinical outcomes. It will be important to
continue to evaluate these relationships and the evolution of other clinical practices (eg,
programming) to further optimize this therapy.
KEY WORDS: Anterior nucleus of the thalamus, Deep brain stimulation, Epilepsy, Targeting
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I

eep brain stimulation (DBS) of the anterior
nucleus of the thalamus (ANT) was recently
approved in the United States for partial
onset epilepsy. The clinical trial (Stimulation
of ANT for Epilepsy, SANTÉ) supporting this
therapy was initiated in 2003 with results first
published in 2010.1 As part of the original

ABBREVIATIONS: ANT, anterior nucleus of the
thalamus; AP, anterior-posterior; DV, dorso-ventral;
MCP, mid-commissural point; MTT, mammillothalamic tract; SANTÉ, Stimulation of ANT for Epilepsy;
STN, subthalamic nucleus; VTA, volume of tissue
activated
Neurosurgery Speaks! Audio abstracts available for this
article at www.neurosurgery-online.com.
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analyses of the trial data, a detailed mapping of
the active DBS contact locations was completed
for each subject, using the standard anterior
commissure-posterior commissure (AC-PC)
based reference space, but comparison of
active contact positions and clinical outcomes
revealed no apparent relationship. Recently,
several reports of ANT-DBS case series using
advanced imaging have described considerable interpatient variability in the location
of this nucleus in relationship to AC-PC
reference space.2-4 In addition to the interpatient variability in position of the ANT, they also
noted considerable deviation compared to the
Schaltenbrand-Wahren atlas, with the nucleus
located more superior and anterior in most
subjects as compared to the atlas specimens.
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This was notable given that, in the SANTÉ trial, indirect targeting
based upon coordinates derived from the Schaltenbrand-Wahren
atlas was used to guide the initial coordinates for lead placement.
Finally, these groups also identified a subregion target within
the ANT, superior to the mammillothalamic tract (MTT) termination, that appeared to be associated with improved outcomes.
These findings prompted us to perform a post hoc re-evaluation
of the lead placements to determine whether there might be a
relationship between patient-specific lead locations and clinical
outcomes in the SANTÉ cohort.

METHODS
The SANTÉ trial (clinicaltrials.gov, identifier NCT00101933) was
approved by the institutional review board (IRB) at all study centers,
and subjects provided written informed consent before participation. Per
the SANTÉ protocol, all subjects (n = 110) had postoperative imaging
and confirmation of bilateral DBS lead placement in the ANT before
entering the randomized treatment phase. For the original assessment of
lead positions, these image sets were used to determine the individual
contact locations of the DBS leads (Model 3387, Medtronic) relative
to the mid-commissural point (MCP) using a neuronavigation system
(StealthStationTM , Medtronic). Active contact positions were defined in
X, Y, Z space for each hemisphere, and these results were then compared
to the clinical outcomes of the individual subjects, who were categorized as responders (≥50% seizure reduction) or nonresponders (<50%
seizure reduction) at 1-yr postimplant. For individuals who had more
than one cathode programmed on a lead (n = 81 left, n = 79 right), the
active contact location was defined as the interpolation of the 2 active
contact positions.
For the new analysis, lead trajectories were assessed qualitatively for
proximity to the ANT subregion target, using axial, coronal, sagittal, and
lead trajectory plane static images. A novel method was devised to aid in
defining the ANT in cases where visualization of anatomic landmarks
(ie, AC, fornix, MTT) was difficult. The thalamus was segmented by
defining the anterior-posterior (AP) and dorso-ventral (DV) axes at a
parasagittal plane through the lead trajectory, and 4 quadrants of an
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ellipse created by outlining the thalamus using these major axes. When
this parasagittal plane is centered on the junction of the MTT with the
ventral border of the nucleus, the ANT occupies most of the anterior,
superior quadrant and extends to, or just past the AP midpoint of the
thalamus (Figure 1).
Lead locations were examined in all subjects for whom adequate
postoperative imaging (n = 103) and 1-yr outcomes (n = 101) were
available. Assessments of lead positions were made by 2 raters who
were blinded to the outcome data. Each lead trajectory was assigned a
score based on the following prospectively defined criteria: 3 = ideal
placement, trajectory passes through the identified subregion target;
2 = slight deviation from ideal placement in one dimension (eg, posterior
or medial) but still within a few millimeters of the target region; 1 = large
deviation from ideal placement (either in multiple dimensions or in one
dimension); 0 = trajectory did not appear to traverse the ANT. Representative examples of the range of lead placements (and scores) are shown
in Figure 2.
Lead positions were assessed in sagittal, axial, and coronal images (in
that hierarchy) and a total score assigned for each subject (range = 06 for bilateral placement). A score of 4 or greater was considered a
good bilateral placement, indicating 2 trajectories near the target region.
Scores below 4 were considered “suboptimal” as at least one lead would
have been rated as deviating considerably from the “ideal” target. Lead
placement scores were then compared to the clinical outcomes during
year 1, defined as the average seizure reduction for 3 2-mo reporting
periods during the unblinded phase (months 7-12). Because the lead
placement scores were ordinal in nature (although they were described
numerically) a categorical analysis (Fisher’s exact test) was conducted.

RESULTS
The original targeting analysis revealed that, despite marked
variability, average active contact locations were comparable to
the coordinates defined as the SANTÉ target (X = 5-6 mm,
Y = 0-2 mm anterior to MCP, Z = 10-12 mm superior to
the intercommissural plane) based on the Schaltenbrand and
Wahren atlas. These coordinates represented the target for the
center of the 3387 lead (ie, the interspace between contacts 1 and
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FIGURE 1. Images of the thalamus illustrating the location of the anterior nucleus within the anterior/dorsal quadrant
created by subdividing the thalamus along the major axes. The mammillothalamic tract (MTT), the main input to the
anterior nucleus, can be seen at the anterior portion of the nucleus in these parasagittal slices (approximately 5 mm lateral
to midline) in an MRI (left) and atlas5 image (right). Other visible white matter landmarks (arrows) include the fornix
and the anterior commissure (AC). The target region is identified by a star in each panel. From Schaltenbrand/Wahren,
Atlas for Stereotaxy of the Human Brain, Georg Thieme Verlag, Stuttgart 1977, with permission.
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2). When compared to the clinical outcomes of the individual
subjects, who were categorized as responders or nonresponders
at 1-yr postimplant, there was no apparent relationship between
active contact location and categorical outcome, with considerable overlap between the 2 groups (Figure 3).
In the new qualitative analysis of lead trajectory positions,
individual scores for bilateral placements ranged from 1 to 6 across
the subject cohort. Overall, out of 103 subjects, nearly 70% had
a score of 4 or greater (good bilateral placement), with the most
common deviations from the “ideal” target being in the medial
and posterior directions (Tables 1 and 2).
The lead placement scores were mapped to each subject’s
clinical outcome (% seizure reduction) during year 1 as shown
in Figure 4, and assessed against the predefined categories for
bilateral placement scores (good vs suboptimal) and clinical
response (>50% reduction in seizures). These categorical
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outcome data are summarized in Table 3. Overall, it was found
that subjects with a score of 4 or greater (ie, “good” bilateral
placement) had a much higher probability of being a clinical
responder than those with a score of 3 or less (43.5% vs
21.9%, P < .05, Fisher’s exact, 2-sided). When assessed across
different subgroups based upon seizure onset location, this trend
remained consistent (temporal onset: 50.0% vs 31.6%; extratemporal onset: 36.4% vs 7.7%) but was not significant due to the
small sample sizes.

DISCUSSION
Accumulating evidence suggests that ANT DBS is an effective,
durable therapy for partial onset epilepsy.6 The original evaluation
of lead placements in the SANTÉ trial, done at the conclusion of
the study, did not suggest a relationship between clinical outcomes
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FIGURE 2. Four examples of individual cases from the SANTÉ trial illustrating different lead trajectories and resultant placement scores. Each case includes 4 images:
sagittal (S), coronal (C), axial (A), and probe’s eye (PE) trajectory views. Representative examples of ideal placement (R lead) score = 3 (top left); slight posterior
placement (L lead) score = 2 (top right); very posterior placement (R lead) score = 1 (bottom left); and very medial placement (L lead) score = 1 (bottom right).

DBS LEAD TARGETING IN SANTÉ

TABLE 1. Distribution of Bilateral Lead Placement Scores
Bilateral score
0
1
2
3
4
5
6

Number of subjects

(%) of subjects

0
2
6
25
24
37
9

0.0%
1.9%
5.8%
24.3%
23.3%
35.9%
8.7%

and active contact location. This analysis was based on contact
position in AC-PC stereotactic space and not on location relative
to thalamic landmarks. Also, a relatively large number of leads
(approximately 80%) were programmed with multiple cathodes.

NEUROSURGERY

TABLE 2. Direction of Individual Lead Placement Deviation From
Ideal Target
Lead placement deviation
Lateral
Medial
Anterior
Posterior

Number of leads

(%) of leads

0
95
5
53

0.0%
46.1%
2.4%
25.7%

To simplify the analysis, the position of the active contact in these
cases was defined as the interpolation of the 2 contacts, based
upon modeling of the stimulation fields. Given the relatively high
stimulation amplitudes (typically 5-7.5 V) and use of multiple
contacts on the 3387 lead (1.5 mm contact spacing), the volume
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FIGURE 3. Results from the original coordinate-based analysis. Left panels show individual subjects’ active contact locations in
the sagittal (top) and axial (bottom) planes for right (circles) and left (squares) leads with responders in blue and nonresponders
in red (n = 94: responders = 43, nonresponders = 51). Right panels show median contact positions and one standard deviation
from the median for both groups.
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TABLE 3. Distribution of Lead Placement Scores for Responders
Versus Nonresponders
Bilateral scorea
3 or < (n = 33)
4 or > (n = 70)

Responder

Nonresponder

21.9%
43.5%

78.1%
56.5%

A small group of subjects (n = 6) had bilateral scores of 4, with a score of 3 on one side
and 1 on the other. Those subjects were evenly distributed between responders and
nonresponders.

a

of tissue activated (VTA) was likely quite large in some of these
subjects. In current practice of ANT DBS, it has become more
common to use the Model 3389 lead (0.5 mm spacing) with
initial stimulation voltages in the 2 to 3 V range on a single contact
and titrate upward if needed,7 based on the size of this nucleus
(similar to subthalamic nucleus (STN)) and modeling estimates
of the resultant VTA.8
Key Results
In the current analysis, patients who had 2 well-placed leads,
based upon their position within the target structure, had a
much greater likelihood of being a clinical responder than
those who did not, independent of seizure onset location. This
result is consistent with experience in other DBS indications,
where accurate lead placement at specific locations within the
target nucleus is important and associated with better clinical
outcomes.9 However, in this case, higher placement scores did
not always favor being a responder. Therefore, good placement
appears to be a necessary, but not sufficient, condition for success.
Other, yet unknown, factors also likely influence individual
patient outcome.
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Interpretation
This new targeting analysis was motivated by recent studies
examining lead location within the ANT, relative to specific
landmarks (eg, MTT) and the relationship with clinical
outcomes.3,7,10,11 Lehtimäki et al3 first identified a subregion
in the anterior portion of the nucleus, superior to the MTT,
which was associated with greater seizure reduction. The MTT
is the main input to the ANT, and the outflow fibers from this
structure exit via the anterior thalamic radiations in the lateral
portion of the nucleus into the internal capsule.12 Stimulation
of contacts in this target area therefore likely activates these
densely packed axonal populations13,14 and, as in other DBS
therapies, results in modulation of broader network activity, in
this case in the Papez circuit. Based on the prior studies demonstrating a subregion within the ANT may be associated with
superior efficacy, we evaluated the SANTÉ dataset in the context
of lead trajectory relative to this target area. We a priori defined a
rating/grading system that classified the lead trajectories relative
to the ANT target region. Trajectories that were through or within
a few millimeters of the target region were considered to be good
placements given that the stimulation voltages used would likely
capture this target region based upon VTA considerations. Trajectories that were more distant from this region were considered
suboptimal. Our intent was to develop a methodology useful
for evaluating ANT implantation, based on categorical methods,
recognizing the variation that has been observed in the ANT DBS
target. The fact that our results were in line with the findings from
4 prior, smaller studies was reassuring.
There was likely a learning curve for placement of DBS
leads in this specific target during the SANTÉ trial as has been
reported for other DBS therapies.15-17 Based on recent experience
in a multicenter European study (MORE Registry), this DBS
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FIGURE 4. Bilateral lead placement scores compared to clinical outcomes (% seizure reduction) for individual
subjects (n = 101). Dotted lines define responder/nonresponder categories and bilateral placement score categories.

DBS LEAD TARGETING IN SANTÉ

Limitations
The results presented here have clear limitations due to the
retrospective, post hoc nature. However, in the spirit of providing
information that can help to improve DBS therapy efficacy and to
benefit patients who elect to undergo the surgery and continued
follow-up associated with DBS, these results add information to
the knowledge base related to this therapy, which at this time
remains fairly limited.
Generalizability
It is universally accepted in movement disorders DBS that
accurate placement of leads into the STN, internal globus
pallidus, or ventral intermediate nucleus is critical for optimal
therapy efficacy. All of these therapies allow for evaluation of lead
location during surgery based on test stimulation results. Unfortunately, for the ANT target, there are no reliable acute stimulation
induced positive effects, nor side effects, to help assess the position
of the leads. However, considering the growing body of evidence
related to targeting and clinical outcomes for this therapy, there
should be no reason to accept suboptimal lead placements given
the ability with current imaging technology to reliably evaluate
lead location either intra- or postoperatively. The significant
benefit observed during the SANTÉ trial, using widely spaced
electrode contacts and suboptimal targeting methods, suggests
an opportunity to improve outcomes with more accurate lead
placement.

NEUROSURGERY

CONCLUSION
The results from this study suggest that a specific area within
the ANT, namely the anterior region, is associated with better
clinical outcomes with DBS. Subjects with good bilateral placements in this target had a higher probability of being a clinical
responder (43.5%) at 1 yr of follow-up, relative to the group
with a suboptimal placement (21.9%). These findings from the
SANTÉ cohort are consistent with earlier reports from smaller
studies, and suggest that a certain degree of specificity in lead
targeting is critical for ensuring a good clinical outcome.
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target appears to have some unique challenges compared to the
traditional movement disorders targets in thalamus, subthalamic
nucleus, and globus pallidus, due to its location at the base of
the ventricle and resultant variability across individual subjects.18
For this reason, in the European study 2 approaches to the ANT
target were utilized, transventricular and extraventricular, based
primarily upon surgeon preference. However, the analysis of lead
locations in the first cohort of 73 subjects revealed that only 71%
of the extraventricular lead placements successfully positioned at
least one contact into the nucleus, compared to 90% with the
transventricular approach.
All of the implants in the SANTÉ study were done using
a transventricular approach, and each case was reviewed by an
independent core lab to ensure that at least one contact of
each lead was in the target nucleus before subjects could be
randomized; 8.2% of the leads needed to be revised based upon
this criterion. However, quadrant or subregion within ANT was
not analyzed and replacement was not mandated so long as one
contact resided somewhere within the ANT. The clinical results
from the SANTÉ trial are comparable to the MORE registry
experience using the same transventricular trajectory, and provide
support for this approach versus the extraventricular trajectory,
even without specifically targeting the area superior to the MTT.
However, improved clinical outcomes may be attainable in the
future, as a result of our study and those of others3,11,19 which
appear to be converging on this target region as the most effective
stimulation site.
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s with other DBS targets, it is logical that there may be a variation
in response based on lead location, and it is intriguing that direct
visualization of structural and anatomic features seemed to correlate
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better with outcome than traditional AC-PC targeting. However, while
statistically significant, the post-hoc nature of the study and relatively
small differences observed make it difficult to interpret how significant
the effect might be. In addition, the definition of “ideal placement”
relative to MTT is highly subjective (including descriptive judgement
calls for “slight” vs. “large” displacement) and the definition of “good”
placement as a score of 4 (which combines “slight” displacement on both
sides with “large” displacement on one side) is somewhat arbitrary. If
would have been much more compelling if the authors had used a more
quantitative measure, such as identifying the putative target location in
each subject and measuring distance of the active contacts from it. It is
also worth noting that a majority of subjects in both groups were nonresponders, and a number of subjects with “good” bilateral placement
actually got worse. The data imply that targeting may indeed impact
efficacy, but more evidence will be necessary to support the efficacy of
this particular target.
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were monitored for degree of symptomatic improvement for more than
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with remarkably higher chance of meaningful clinical response with
almost 2-fold difference between those with optimal and suboptimal
location of stimulating contacts.
To further improve individual outcomes, one will need to develop
either an easily identifiable set of radiographic landmarks, or a reliable
neurophysiological indicator of the target. Alternatively, one may use
technological advancement in electrode leads (directional, segmented,
etc) to compensate for inaccurate targeting.
It would be interesting to extend this analysis to hundreds of patients
implanted with ANT DBS outside of SANTÉ trial to see if the authors’
findings are indeed valid.
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